Additional Levy Means Further Burden For DrugmakersJune 2012 | Industry Trend Analysis
BMI View: Drugmakers previously disheartened by the extent of cuts to Hungary's National Healthcare Fund (OEP) will be further aggrieved by a new bill that proposes increasing the levies paid on some reimbursed drugs to 30%. We have previously discussed our scepticism regarding the Hungarian government's seemingly unachievable cuts to the OEP, which remains the case, while the latest bill is a further demonstration of the government shifting the financial cost of medicines back on to drugmakers. The changes in the legislation negatively affect pharmaceutical companies and market authorisation holders, while other aspects of the bill are positive for larger pharmacies.
To read the full article, please choose one of the following options: